New and emerging treatments for PBC-related pruritus.

Drugs Context · 2026 · PMC13225309 · PMID 42232646

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

6 Elafibranor Elafibranor, a dual PPARα and PPARδ agonist approved by the FDA in June 2024 and by the EMA in September 2024 for the treatment of PBC, 26 , 27 showed a numerical trend towards pruritus improvement but did not achieve statistical significance for its primary pruritus end point.

also in 723 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.